Vaderis Forms to Tackle Vascular Malformations with Novartis Vet at the Helm

With financial backing from Medicxi, Vaderis Therapeutics AG emerged from stealth mode Monday with a focus on allosteric AKT inhibitors and a clinic-ready drug candidate.

The young biotech plans to launch a proof-of-concept clinical trial assessing its lead asset VAD044 in patients suffering from Hereditary Hemorrhagic Telangiectasia (HHT).